ArticleJournal of vascular surgery cases and innovative techniques2026
Application of the Auersvald hemostatic net in arteriovenous fistula revision to prevent hematoma formation.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative hematoma is a frequent complication of arteriovenous fistula (AVF) revision, threatening wound healing and access patency. The Auersvald hemostatic net is commonly used in rhytidoplasty for hematoma prevention. We report its innovative application in a high-risk patient undergoing AVF revision under supratherapeutic anticoagulation, with aneurysmal degeneration and friable tissue from light chain amyloidosis. Given the elevated bleeding risk and drain displacement concerns, the net was applied after hematoma evacuation to obliterate dead space and provide mechanical hemostasis. No postoperative hematoma developed, and dialysis resumed at 5 weeks, suggesting utility as a drain alternative in select high-risk patients with an AVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.